[New derivative of nitromidazole-tinidazole, for the treatment of giardiasis].
The author treated 100 patients infected by Giardia lamblia with a new antiprotozoal agent: Tinidazole. The patients were divided in two groups: Group I, composed of 50 patients were divided with a dosage of 300 mgm per day for seven consecutive days. The author obtained a cure rate of 96% (48 cases), and minimal side-effects were observed in 10% of the cases: nausea and headache, Group II also composed of 50 patients which were treated with a single dose of 2,0 gm. The parasitological cure obtained was around 90% (45 patients) and the tolerance to the drug was very good. To evaluate the cure, the methods of Faust et al. and Hoffman, Pons & Janer, such as spontaneous sedimentation in water, were used, 7, 14 and 21 días after treatment. The author concluded that the new antiprotozoal agent is an excellent drug against Giardia lamblia infections.
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D004341:Drug Evaluation; D005260:Female; D005873:Giardiasis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009593:Nitroimidazoles / Q000627:therapeutic use*; D014011:Tinidazole / Q000009:adverse effects / Q000037:antagonists & inhibitors / Q000627:therapeutic use*
D009593:Nitroimidazoles; D014011:Tinidazole
Novo derivado nitroimidazolico-tinidazol, para o tratamento da giardiase.